A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.
Epistemonikos ID: 59424c04daf74f7798e9146dc0baa64f9c95c715
First added on: May 15, 2024